REPAIRING GENES, RESTORING STRENGTH: THE PROMISE OF MODERN GENE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY

Keywords: Duchenne Muscular Dystrophy, Delandistrogene Moxeparvovec, Gene Therapy, Skeletal Muscle Function, Genetic Disorders, Dystrophin

Abstract

Introduction: Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disorder characterized by progressive muscle degeneration due to mutations in the dystrophin gene. Current treatments primarily focus on symptom management. Delandistrogene moxeparvovec is a gene therapy designed to deliver a shortened, functional version of the dystrophin gene, potentially modifying disease progression.

Aim of the study: To evaluate the clinical efficacy and safety of delandistrogene moxeparvovec in improving skeletal muscle function and physical performance in patients with DMD based on data from completed clinical trials.

Methodology: The analysis includes four published clinical trials involving ambulatory boys aged 4–8 years with confirmed dystrophin mutations. Primary outcomes focused on changes in the North Star Ambulatory Assessment (NSAA), while secondary endpoints included time to rise from the floor and the 10-meter walk/run test. Study designs ranged from open-label to randomized, double-blind trials. Adverse events and regulatory outcomes were also considered.

Conclusions: Delandistrogene moxeparvovec demonstrated variable improvements in motor function, with more pronounced benefits in younger age groups. Some trials showed statistically significant results, while others failed to meet primary endpoints. Adverse events, including serious complications, were reported. The therapy received FDA approval in 2023 and 2024 for defined patient subgroups, though some decisions were made despite inconclusive efficacy data.

References

Bez Batti Angulski A, Hosny N, Cohen H, Martin AA, Hahn D, Bauer J, et al. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front Physiol. 2023;14:1183101. DOI: 10.3389/fphys.2023.1183101

Shih JA, Folch A, Wong BL. Duchenne Muscular Dystrophy: the Heart of the Matter. Curr Heart Fail Rep. 2020;17(3):57-66. DOI: 10.1007/s11897-020-00456-0

Aldharee H. Duchenne muscular dystrophy in Saudi Arabia: a review of the current literature. Front Neurol. 2024;15:1392274. DOI: 10.3389/fneur.2024.1392274

Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13. DOI: 10.1038/s41572-021-00248-3.

Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-67. DOI: 10.1016/S1474-4422(18)30024-3

Patterson G, Conner H, Groneman M, Blavo C, Parmar MS. Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach. Eur J Pharmacol. 2023;947:175675. DOI: 10.1016/j.ejphar.2023.175675

Trucco F, Domingos JP, Tay CG, Ridout D, Maresh K, Munot P, et al. Cardiorespiratory Progression Over 5 Years and Role of Corticosteroids in Duchenne Muscular Dystrophy: A Single-Site Retrospective Longitudinal Study. Chest. 2020;158(4):1606-16. DOI: 10.1016/j.chest.2020.04.043

Mendell JR, Shieh PB, McDonald CM, Sahenk Z, Lehman KJ, Lowes LP, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol. 2023;11:1167762. DOI: 10.3389/fcell.2023.1167762

Mendell JR, Sahenk Z, Lehman KJ, Lowes LP, Reash NF, Iammarino MA, et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial. Muscle Nerve. 2024;69(1):93-8. DOI: 10.1002/mus.27955

Mercuri E, Bönnemann CG, Muntoni F. Muscular dystrophies. Lancet. 2019;394(10213):2025-38. DOI: 10.1016/S0140-6736(19)32910-1

Nevin NC, Hughes AE, Calwell M, Lim JH. Duchenne muscular dystrophy in a female with a translocation involving Xp21. J Med Genet. 1986;23(2):171-3. DOI: 10.1136/jmg.23.2.171

Górecki DC, Monaco AP, Derry JM, Walker AP, Barnard EA, Barnard PJ. Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters. Hum Mol Genet. 1992;1(7):505-10. DOI: 10.1093/hmg/1.7.505

Chelly J, Hamard G, Koulakoff A, Kaplan JC, Kahn A, Berwald-Netter Y. Dystrophin gene transcribed from different promoters in neuronal and glial cells. Nature. 1990;344(6261):64-5. DOI: 10.1038/344064a0

Gao QQ, McNally EM. The Dystrophin Complex: Structure, Function, and Implications for Therapy. Compr Physiol. 2015;5(3):1223-39. DOI: 10.1002/cphy.c140048

Aartsma-Rus A, van Putten M. Assessing functional performance in the mdx mouse model. J Vis Exp. 2014(85). DOI: 10.3791/51303

Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, Thomas GD, et al. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 2000;97(25):13818-23. DOI: 10.1073/pnas.250379497

Klietsch R, Ervasti JM, Arnold W, Campbell KP, Jorgensen AO. Dystrophin-glycoprotein complex and laminin colocalize to the sarcolemma and transverse tubules of cardiac muscle. Circ Res. 1993;72(2):349-60. DOI: 10.1161/01.res.72.2.349

Thangarajh M, Hendriksen J, McDermott MP, Martens W, Hart KA, Griggs RC. Relationships between DMD mutations and neurodevelopment in dystrophinopathy. Neurology. 2019;93(17):e1597-e604. DOI: 10.1212/WNL.0000000000008363

McDonald CM, Marden JR, Shieh PB, Wong BL, Lane H, Zhang A, et al. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status. J Comp Eff Res. 2023;12(4):e220190. DOI: 10.57264/cer-2022-0190

Zelikovich AS, Joslin BC, Casey P, McNally EM, Ajroud-Driss S. An Open Label Exploratory Clinical Trial Evaluating Safety and Tolerability of Once-Weekly Prednisone in Becker and Limb-Girdle Muscular Dystrophy. J Neuromuscul Dis. 2022;9(2):275-87. DOI: 10.3233/JND-210741

Guglieri M, Clemens PR, Perlman SJ, Smith EC, Horrocks I, Finkel RS, et al. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA Neurol. 2022;79(10):1005-14. DOI: 10.1001/jamaneurol.2022.2480

Syed N, Un Nisa Mughal Z, Haseeb A, Alemam Manhal G, Yasir Eissa A, Abbasher Hussien Mohamed Ahmed K. Duvyzat (givinostat): a new hope for Duchenne muscular dystrophy patients. Ann Med Surg (Lond). 2025;87(5):2529-31. DOI: 10.1097/MS9.0000000000003196

EMA. New treatment against Duchenne muscular dystrophy 2025 [cited 2025 09.07]. Available from: https://www.ema.europa.eu/en/news/new-treatment-against-duchenne-muscular-dystrophy?utm_source.

Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015;36(4):395-402. DOI: 10.1002/humu.22758

Mercuri E, Osorio AN, Muntoni F, Buccella F, Desguerre I, Kirschner J, et al. Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015-2022): 2022 interim analysis. J Neurol. 2023;270(8):3896-913. DOI: 10.1007/s00415-023-11687-1

Bello L, Riguzzi P, Albamonte E, Astrea G, Battini R, Barp A, et al. Opinion of the Italian Association of Myology on Ataluren for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy. Drugs R D. 2025;25(2):99-106. DOI: 10.1007/s40268-025-00512-x

EMA. EMA decision to not renew the conditional marketing authorisation for Translarna (ataluren) in the European Union (EU) 2025 [cited 2025 09.07]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/translarna?utm_source.

Aoki Y, Wood MJA. Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases. J Neuromuscul Dis. 2021;8(6):869-84. DOI: 10.3233/JND-200560

Roshmi RR, Yokota T. Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience. Clin Pharmacol. 2021;13:235-42. DOI: 10.2147/CPAA.S288842

Szwec S, Kapłucha Z, Chamberlain JS, Konieczny P. Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review. BioDrugs. 2024;38(1):95-119. DOI: 10.1007/s40259-023-00632-3

Morin A, Stantzou A, Petrova ON, Hildyard J, Tensorer T, Matouk M, et al. Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle. Proc Natl Acad Sci U S A. 2023;120(2):e2206324120. DOI: 10.1073/pnas.2206324120

Bönnemann CG, Belluscio BA, Braun S, Morris C, Singh T, Muntoni F. Dystrophin Immunity after Gene Therapy for Duchenne's Muscular Dystrophy. N Engl J Med. 2023;388(24):2294-6. DOI: 10.1056/NEJMc2212912

Bennett J. Overview of Retinal Gene Therapy: Current Status and Future Challenges. Cold Spring Harb Perspect Med. 2023;13(7). DOI: 10.1101/cshperspect.a041278

Ramos JN, Hollinger K, Bengtsson NE, Allen JM, Hauschka SD, Chamberlain JS. Development of Novel Micro-dystrophins with Enhanced Functionality. Mol Ther. 2019;27(3):623-35. DOI: 10.1016/j.ymthe.2019.01.002

Zaidman CM, Goedeker NL, Aqul AA, Butterfield RJ, Connolly AM, Crystal RG, et al. Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2024;11(3):687-99. DOI: 10.3233/JND-230185

Bhattacharyya M, Miller LE, Miller AL, Bhattacharyya R. The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process. Expert Opin Biol Ther. 2024;24(9):869-71. DOI: 10.1080/14712598.2024.2394477

Ayyar Gupta V, Pitchforth JM, Domingos J, Ridout D, Iodice M, Rye C, et al. Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy. PLoS One. 2023;18(4):e0283669. DOI: 10.1371/journal.pone.0283669

Zaidman CM, Proud CM, McDonald CM, Lehman KJ, Goedeker NL, Mason S, et al. Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR). Ann Neurol. 2023;94(5):955-68. DOI: 10.1002/ana.26755

Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025;31(1):332-41. DOI: 10.1038/s41591-024-03304-z

Mendell JR, Proud C, Zaidman CM, Mason S, Darton E, Wang S, et al. Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy.

Pediatr Neurol. 2024;153:11-8. DOI: 10.1016/j.pediatrneurol.2024.01.003

Oskoui M, Caller TA, Parsons JA, Servais L, Butterfield RJ, Bharadwaj J, et al. Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus. Neurology. 2025;104(11):e213604. DOI: 10.1212/WNL.0000000000213604

Crossnohere NL, Fischer R, Vroom E, Furlong P, Bridges JFP. A Comparison of Caregiver and Patient Preferences for Treating Duchenne Muscular Dystrophy. Patient. 2022;15(5):577-88. DOI: 10.1007/s40271-022-00574-y

Views:

33

Downloads:

22

Published
2025-07-16
Citations
How to Cite
Katarzyna Kozon, Agnieszka Floriańczyk, Ewa Romanowicz, Aleksandra Kołdyj, Agnieszka Ozdarska, Adrian Krzysztof Biernat, Marcin Lampart, Anna Rupińska, Zuzanna Jasińska, & Kamila Krzewska. (2025). REPAIRING GENES, RESTORING STRENGTH: THE PROMISE OF MODERN GENE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY. International Journal of Innovative Technologies in Social Science, (3(47). https://doi.org/10.31435/ijitss.3(47).2025.3468

Most read articles by the same author(s)